gene

apoe

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about apoe: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

4804Connections
29Hypotheses
24Analyses
3Outgoing
2Incoming

Summary

Apolipoprotein E (APOE) is the primary cholesterol carrier in the brain, essential for lipid transport, neuronal repair, and synaptic maintenance. The APOE gene has three common alleles: APOE2, APOE3, and APOE4. APOE4 is the strongest genetic risk factor for late-onset Alzheimer's disease, increasing risk 3-15 fold depending on copy number. APOE4 impairs amyloid-beta clearance, promotes neuroinflammation, disrupts blood-brain barrier integrity, and reduces cerebrovascular function. APOE2 is protective, enhancing amyloid clearance and reducing tau pathology. Therapeutic strategies include APOE4 structure correctors, gene therapy to convert APOE4 to APOE3, and anti-APOE4 antibodies.

View on Wiki →

🧬 Gene Info
Gene SymbolAPOE
Full NameApolipoprotein E
Chromosome19q13.32
Target ClassLigand
FunctionIt binds to the LDL receptor family to facilitate uptake of lipoprotein particles.
Mechanism of ActionProtein-protein interaction modulator or lipid metabolism enhancer
DruggabilityMedium (0.47)
Clinical StagePhase II
Molecular Weight34 kDa
PathwaysAmyloid, Autophagy, Blood-Brain Barrier, Brain Lipid Metabolism, Cholesterol
GeneCardsAPOE
Human Protein AtlasAPOE
GenotypeAD Risk
ε3/ε3Baseline (1x)
ε3/ε4~3x increased
Associated DiseasesAD, AGING, ALS, ALZHEIMER, ALZHEIMER'S DISEASE, AMI
Known Drugs/CompoundsLIPOPROTEINS, Lipid-Targeting Therapeutic Strategies, LECANEMAB, RESVERATROL, CURCUMIN, Gene Therapy
InteractionsLRP1, LDLR, LOX, IL6, SREBF1, PSEN2
SciDEX TargetView Target Profile (8 clinical trials)
SciDEX HypothesesAPOE4-Specific Lipidation Enhancement Therapy
Prime Editing Precision Correction of APOE4 to APO
Selective APOE4 Degradation via Proteolysis Target (+11 more)
KG Connections4776 knowledge graph edges
DatabasesGeneCardsUniProtNCBI GeneHPASTRING
🧬 3D Structure: apoe — PDB 2L7B Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

APOE — Apolipoprotein E

gene · 2267 words

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

therapeutic · 15794 words

Corticobasal Syndrome (CBS)

disease · 11374 words

Novel Therapy Index

idea · 10647 words

Microglia CD8+ T Cell Recruitment -- Supplementary WW Content

mechanism · 7227 words

Atypical Parkinsonism

disease · 6876 words

Pathway Diagram

graph TD
    APOE["APOE"]
    APOE -->|"produces"| microRNAs["microRNAs"]
    APOE -->|"activates"| histone_acetylation["histone acetylation"]
    APOE -.protects against.-> ferroptosis["ferroptosis"]
    APOE -.biomarker for.-> ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
    APOE -->|"contributes to"| Alzheimer_s_disease["Alzheimer's disease"]
    APOE -->|"activates"| MHC_I["MHC-I"]
    APOE -->|"causes"| SELECTIVE_NEURODEGENERATION["SELECTIVE NEURODEGENERATION"]
    APOE -->|"causes"| lipoprotein_glomerulopathy["lipoprotein glomerulopathy"]
    APOE -->|"causes"| neurodegeneration["neurodegeneration"]
    APOE -->|"inhibits"| cholesterol_biosynthesis["cholesterol biosynthesis"]
    h_b948c32c["h-b948c32c"] -->|"target for"| APOE
    h_44195347["h-44195347"] -->|"target for"| APOE
    h_d0a564e8["h-d0a564e8"] -->|"target for"| APOE
    h_11795af0["h-11795af0"] -->|"target for"| APOE
    h_99b4e2d2["h-99b4e2d2"] -->|"target for"| APOE
    h_a20e0cbb["h-a20e0cbb"] -->|"target for"| APOE
    TREM2["TREM2"] -->|"participates in"| APOE
    siRNA["siRNA"] -->|"inhibits"| APOE

Outgoing (3379)

TargetRelationTypeStr
neurodegenerationimplicated_indisease0.50
ad_genetic_risk_loci:APOEdata_indataset_row0.00
benchmark_ot_ad_answer_key:APOEdata_indataset_row0.00

Incoming (1425)

SourceRelationTypeStr
ad_genetic_risk_loci:APOEdata_indataset_row0.00
benchmark_ot_ad_answer_key:APOEdata_indataset_row0.00

Targeting Hypotheses (29)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
APOE4-Specific Lipidation Enhancement Therapy 0.845 Alzheimer's disease -
Prime Editing Precision Correction of APOE4 to APOE3 in Micr 0.622 neurodegeneration CRISPR-based therapeutic approaches for
APOE-Dependent Autophagy Restoration 0.615 neurodegeneration Mechanistic role of APOE in neurodegener
Selective APOE4 Degradation via Proteolysis Targeting Chimer 0.595 neurodegeneration APOE4 structural biology and therapeutic
H1: TREM2 Agonism to Redirect APOE4-Enhanced Microglia from 0.588 neurodegeneration How does APOE4's beneficial immune funct
GPC4/HSPGs Collaborate with ApoE Isoforms to Dictate Tau Con 0.583 neurodegeneration What are the specific molecular determin
CLU/APOE Duality in Amyloid Clearance Determines Cell-Type-S 0.576 neurodegeneration What are the cell-type-specific transcri
Competitive APOE4 Domain Stabilization Peptides 0.561 neurodegeneration APOE4 structural biology and therapeutic
APOE4 Isoform Correction via Lipidation Enhancement as CTE R 0.552 neurodegeneration What genetic risk factors predispose ind
CLU-APOE-TREM2 Tripartite Axis as a Coordinate Therapeutic T 0.548 neurodegeneration Does clusterin exacerbate or protect aga
HDL/apoE Particle Remodeling as a Therapeutic Switch for CAA 0.544 neurodegeneration What molecular mechanisms explain how ap
APOE4 Allosteric Rescue via Small Molecule Chaperones 0.542 neurodegeneration APOE4 structural biology and therapeutic
Astrocyte-Selective APOE4 Silencing via Lipid Nanoparticles 0.529 neurodegeneration Which cell types show the most significa
Targeted APOE4-to-APOE3 Base Editing Therapy 0.526 neurodegeneration APOE4 structural biology and therapeutic
LXRβ-Selective Agonism as a Precision Therapeutic for APOE4- 0.505 neurodegeneration What specific molecular mechanisms link
APOE4-Specific Microglial Metabolic Rescue 0.498 - Neuroinflammation and microglial priming
Proteostasis Enhancement via APOE Chaperone Targeting 0.496 neurodegeneration Mechanistic role of APOE in neurodegener
TREM2-APOE4 Co-targeting — Simultaneous Correction of Lipid 0.486 Alzheimer's disease TREM2 agonism vs antagonism in DAM micro
APOE4-Selective Lipid Nanoemulsion Therapy 0.486 neurodegeneration Mechanistic role of APOE in neurodegener
Chaperone-Mediated APOE4 Refolding Enhancement 0.482 neurodegeneration APOE4 structural biology and therapeutic
APOE-TREM2 Interaction Modulation 0.479 neurodegeneration Mechanistic role of APOE in neurodegener
Astrocyte APOE4-Specific Lipid Metabolism Correction 0.479 neurodegeneration Cell type vulnerability in Alzheimers Di
APOE Isoform Expression Across Glial Subtypes 0.476 Alzheimer's Disease SEA-AD Gene Expression Profiling — Allen
APOE4-Driven Astrocyte Senescence as Primary Target 0.460 - Senescent cell clearance as neurodegener
Astrocyte Metabolic Reprogramming via APOE4 Correction 0.451 neurodegeneration Cell type vulnerability in Alzheimer's D
APOE Isoform Conversion Therapy 0.437 neurodegeneration Mechanistic role of APOE in neurodegener
APOE-Mediated Synaptic Lipid Raft Stabilization 0.426 neurodegeneration Mechanistic role of APOE in neurodegener
APOE4-Lipid Metabolism Correction 0.425 neurodegeneration Neuroinflammation and microglial priming
Pharmacological Enhancement of APOE4 Glycosylation 0.366 neurodegeneration APOE4 structural biology and therapeutic

Mentioning Analyses (24)

Scientific analyses that reference this entity

Does APOE4 drive tau propagation

neurodegeneration | 2026-04-16 | 0 hypotheses

Does APOE4 drive tau propagation

neurodegeneration | 2026-04-15 | 0 hypotheses

What molecular mechanisms explain how apoE promotes cerebral amyloid angiopathy

neurodegeneration | 2026-04-15 | 1 hypotheses Top: 0.544

What specific molecular mechanisms link APOE4 to cholesterol dysregulation in ol

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.505

How does APOE4's beneficial immune function reconcile with its established role

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.588

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] Litvinchuk A, Suh JH, Guo JL, Lin K, Dav Neuron 2024 1
The cell biology of APOE in the brain. [PMID:37805344] Windham IA, Cohen S Trends Cell Biol 2024 1
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] Maxine R Nelson, Peng Liu, Ayushi Agrawa Nature neuroscience 2023 1
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] Serrano-Pozo A, Das S, Hyman BT Lancet Neurol 2021 1
Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] Banik SM, Pedram K, Wisnovsky S, Ahn G, Nature 2020 1
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] Long JM, Holtzman DM Cell 2019 1
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] Yamazaki Y, Zhao N, Caulfield TR, Liu CC Nat Rev Neurol 2019 1
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] Cetindag AC, Schipke CG, Esselmann H, Kr The journal of prevention of A 2026 0
Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] Thedim M, Hu J, Maher M, Wiener-Kronish Br J Anaesth 2026 0
Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] Bae H, Song Z, Ali A, Sasaki T, Tesi N e Geroscience 2026 0
Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] Stern A, Linial M Geroscience 2026 0
Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasi [PMID:40886963] Zhu L, Du L, Wu J, Ding D, Wang J et al. J Invest Dermatol 2026 0
Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsu [PMID:41101204] Sang Y, Cao Y, Li S, Quan Y, Wang S et a Biomaterials 2026 0
Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β path [PMID:41445196] Lin Z, Xiong J, Zhang F, Zhang H, Zhu M Mol Ther 2026 0
Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227] Samudra N, Vemuri M, Weitlauf J Curr Opin Obstet Gynecol 2026 0
ApoE-directed CpG nano-immunoadjuvant ameliorates Alzheimer's-like pathology in [PMID:41651379] Huang X, Sun YY, Qin YR, Chen H, Pan TT J Control Release 2026 0
Albofungin vesicle nanobombs trigger lysosomal disruption for self-enhanced pyro [PMID:41679437] Chen C, Tan S, Zhu X, Song Z, Xing Y et J Control Release 2026 0
Covalent Bond Locking in Semiconducting Oligomers Boosts Ultrabright NIR-II Lumi [PMID:41757652] Li X, Gan H, Zhang C, Gao Y, Zhang J et Angew Chem Int Ed Engl 2026 0
Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pa [PMID:41930593] Yoshida K, Saito N, Takahashi R, Ando S, J Alzheimers Dis 2026 0
UBE2I Alleviates Pyroptosis in Coronary Heart Disease by Promoting the SUMOylati [PMID:41930933] Ding SK Immunol Invest 2026 0